Literature DB >> 25954113

Proton pump inhibitors in prevention of low-dose aspirin-associated upper gastrointestinal injuries.

Chen Mo1, Gang Sun1, Ming-Liang Lu1, Li Zhang1, Yan-Zhi Wang1, Xi Sun1, Yun-Sheng Yang1.   

Abstract

AIM: To determine the preventive effect and safety of proton pump inhibitors (PPIs) in low-dose aspirin (LDA)-associated gastrointestinal (GI) ulcers and bleeding.
METHODS: We searched MEDLINE, EMBASE and the Cochrane Controlled Trials Register from inception to December 2013, and checked conference abstracts of randomized controlled trials (RCTs) on the effect of PPIs in reducing adverse GI events (hemorrhage, ulcer, perforation, or obstruction) in patients taking LDA. The preventive effects of PPIs were compared with the control group [taking placebo, a cytoprotective agent, or an H2 receptor antagonist (H2RA)] in LDA-associated upper GI injuries. The meta-analysis was performed using RevMan 5.1 software.
RESULTS: We evaluated 8780 participants in 10 RCTs. The meta-analysis showed that PPIs decreased the risk of LDA-associated upper GI ulcers (OR = 0.16; 95%CI: 0.12-0.23) and bleeding (OR = 0.27; 95%CI: 0.16-0.43) compared with control. For patients treated with dual anti-platelet therapy of LDA and clopidogrel, PPIs were able to prevent the LDA-associated GI bleeding (OR = 0.36; 95%CI: 0.15-0.87) without increasing the risk of major adverse cardiovascular events (MACE) (OR = 1.00; 95%CI: 0.76-1.31). PPIs were superior to H2RA in prevention of LDA-associated GI ulcers (OR = 0.12; 95%CI: 0.02-0.65) and bleeding (OR = 0.32; 95%CI: 0.13-0.79).
CONCLUSION: PPIs are effective in preventing LDA-associated upper GI ulcers and bleeding. Concomitant use of PPI, LDA and clopidogrel did not increase the risk of MACE.

Entities:  

Keywords:  Gastrointestinal bleeding; Low dose aspirin; Meta-analyses; Peptic ulcer; Proton pump inhibitor; Randomized controlled trial

Mesh:

Substances:

Year:  2015        PMID: 25954113      PMCID: PMC4419080          DOI: 10.3748/wjg.v21.i17.5382

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  31 in total

1.  Omeprazole affects clopidogrel efficacy but not ischemic events in patients with acute coronary syndrome undergoing elective percutaneous coronary intervention.

Authors:  Yi-hong Ren; Ming Zhao; Yun-dai Chen; Lian Chen; Hong-bin Liu; Yu Wang; Zhi-jun Sun; Jin-song Chen; Ting-ting Huang; Yu-song Guo; Yong-jin Xie; Chun-ya Wang
Journal:  Chin Med J (Engl)       Date:  2011-03       Impact factor: 2.628

Review 2.  ACCF/ACG/AHA 2010 Expert Consensus Document on the concomitant use of proton pump inhibitors and thienopyridines: a focused update of the ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use: a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents.

Authors:  Neena S Abraham; Mark A Hlatky; Elliott M Antman; Deepak L Bhatt; David J Bjorkman; Craig B Clark; Curt D Furberg; David A Johnson; Charles J Kahi; Loren Laine; Kenneth W Mahaffey; Eamonn M Quigley; James Scheiman; Laurence S Sperling; Gordon F Tomaselli
Journal:  Circulation       Date:  2010-11-08       Impact factor: 29.690

3.  Influence of omeprazol on the antiplatelet action of clopidogrel associated to aspirin.

Authors:  M Gilard; B Arnaud; G Le Gal; J F Abgrall; J Boschat
Journal:  J Thromb Haemost       Date:  2006-08-08       Impact factor: 5.824

4.  Clinical events as a function of proton pump inhibitor use, clopidogrel use, and cytochrome P450 2C19 genotype in a large nationwide cohort of acute myocardial infarction: results from the French Registry of Acute ST-Elevation and Non-ST-Elevation Myocardial Infarction (FAST-MI) registry.

Authors:  Tabassome Simon; Philippe Gabriel Steg; Martine Gilard; Didier Blanchard; Laurent Bonello; Michel Hanssen; Hervé Lardoux; Pierre Coste; Thierry Lefèvre; Elodie Drouet; Geneviève Mulak; Vincent Bataille; Jean Ferrières; Céline Verstuyft; Nicolas Danchin
Journal:  Circulation       Date:  2011-01-24       Impact factor: 29.690

5.  Ulcer recurrence in high-risk patients receiving nonsteroidalanti-inflammatory drugs plus low-dose aspirin: results of a post HOC subanalysis.

Authors:  Jay L Goldstein; Bidan Huang; Fouad Amer; Nikos G Christopoulos
Journal:  Clin Ther       Date:  2004-10       Impact factor: 3.393

6.  Clinical outcomes in patients with the concomitant use of clopidogrel and proton pump inhibitors after percutaneous coronary intervention: an analysis from the Guthrie Health Off-Label Stent (GHOST) investigators.

Authors:  Kishore J Harjai; Chetan Shenoy; Pam Orshaw; Samer Usmani; Judy Boura; Rajendra H Mehta
Journal:  Circ Cardiovasc Interv       Date:  2011-03-08       Impact factor: 6.546

7.  Effect of antisecretory drugs and nitrates on the risk of ulcer bleeding associated with nonsteroidal anti-inflammatory drugs, antiplatelet agents, and anticoagulants.

Authors:  Angel Lanas; Luis A García-Rodríguez; Maria T Arroyo; Luis Bujanda; Fernando Gomollón; Montserrat Forné; Sofía Aleman; David Nicolas; Faust Feu; Antonio González-Pérez; Ana Borda; Manuel Castro; Maria Jose Poveda; Juan Arenas
Journal:  Am J Gastroenterol       Date:  2007-03       Impact factor: 10.864

8.  Efficacy of esomeprazole (20 mg once daily) for reducing the risk of gastroduodenal ulcers associated with continuous use of low-dose aspirin.

Authors:  Neville Yeomans; Angel Lanas; Joachim Labenz; Sander Veldhuyzen van Zanten; Christoffel van Rensburg; Istvan Rácz; Konstantin Tchernev; Dimitrios Karamanolis; Enrico Roda; Chris Hawkey; Emma Nauclér; Lars-Erik Svedberg
Journal:  Am J Gastroenterol       Date:  2008-07-12       Impact factor: 10.864

9.  Lansoprazole for the prevention of recurrences of ulcer complications from long-term low-dose aspirin use.

Authors:  Kam Chuen Lai; Shiu Kum Lam; Kent Man Chu; Benjamin C Y Wong; Wai Mo Hui; Wayne H C Hu; George K K Lau; Wai Man Wong; Man Fung Yuen; Annie O O Chan; Ching Lung Lai; John Wong
Journal:  N Engl J Med       Date:  2002-06-27       Impact factor: 91.245

10.  Prevention of peptic ulcers with esomeprazole in patients at risk of ulcer development treated with low-dose acetylsalicylic acid: a randomised, controlled trial (OBERON).

Authors:  James M Scheiman; P J Devereaux; Johan Herlitz; Peter H Katelaris; Angel Lanas; Sander Veldhuyzen van Zanten; Emma Nauclér; Lars-Erik Svedberg
Journal:  Heart       Date:  2011-03-17       Impact factor: 5.994

View more
  26 in total

Review 1.  The Indications, Applications, and Risks of Proton Pump Inhibitors.

Authors:  Joachim Mössner
Journal:  Dtsch Arztebl Int       Date:  2016-07-11       Impact factor: 5.594

2.  Is proton pump inhibitors' prophylaxis indicated for patients on antiplatelet therapy?

Authors:  Lorenzo Porta; Francesca Baorda; Alessandra Fusco
Journal:  Intern Emerg Med       Date:  2018-03-16       Impact factor: 3.397

3.  Relationship between Adverse Gastric Reactions and the Timing of Enteric-Coated Aspirin Administration.

Authors:  Weijun Guo; Wenlin Lu; Yujun Xu; Liansheng Wang; Qin Wei; Qingyun Zhao
Journal:  Clin Drug Investig       Date:  2017-02       Impact factor: 2.859

4.  Antithrombotic Therapy: Prevention and Treatment of Atherosclerosis and Atherothrombosis.

Authors:  R H Olie; P E J van der Meijden; H M H Spronk; H Ten Cate
Journal:  Handb Exp Pharmacol       Date:  2022

Review 5.  Implications of the heterogeneity between guideline recommendations for the use of low dose aspirin in primary prevention of cardiovascular disease.

Authors:  Xiao-Ying Li; Li Li; Sang-Hoon Na; Francesca Santilli; Zhongwei Shi; Michael Blaha
Journal:  Am J Prev Cardiol       Date:  2022-06-06

6.  Efficacy and Safety of Proton Pump Inhibitors in Patients With Coronary Artery Diseases Receiving Oral Antiplatelet Agents and/or Anticoagulants: A Systematic Review and Meta-Analysis.

Authors:  Yao-Sheng Shang; Peng-Yu Zhong; Ying Ma; Nan Bai; Ying Niu; Zhi-Lu Wang
Journal:  J Cardiovasc Pharmacol       Date:  2022-07-01       Impact factor: 3.271

7.  Influence of proton pump inhibitors and histamine H2 receptor antagonists on serum phosphorus level control by calcium carbonate in patients undergoing hemodialysis: a retrospective medical chart review.

Authors:  Masaomi Tatsuzawa; Ryuichi Ogawa; Atsushi Ohkubo; Kazuyo Shimojima; Kunimi Maeda; Hirotoshi Echizen; Akihisa Miyazaki
Journal:  J Pharm Health Care Sci       Date:  2016-11-22

8.  Long-term use of proton pump inhibitors and prevalence of disease- and drug-related reasons for gastroprotection-a cross-sectional population-based study.

Authors:  Susanna M Wallerstedt; Johan Fastbom; Johannes Linke; Sigurd Vitols
Journal:  Pharmacoepidemiol Drug Saf       Date:  2016-11-16       Impact factor: 2.890

Review 9.  Bleeding Risk with Long-Term Low-Dose Aspirin: A Systematic Review of Observational Studies.

Authors:  Luis A García Rodríguez; Mar Martín-Pérez; Charles H Hennekens; Peter M Rothwell; Angel Lanas
Journal:  PLoS One       Date:  2016-08-04       Impact factor: 3.240

10.  Age-specific risks, severity, time course, and outcome of bleeding on long-term antiplatelet treatment after vascular events: a population-based cohort study.

Authors:  Linxin Li; Olivia C Geraghty; Ziyah Mehta; Peter M Rothwell
Journal:  Lancet       Date:  2017-06-13       Impact factor: 79.321

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.